Expression of MDR1, HIF-1 and MRP1 in sacral chordoma and chordoma cell line CM-319

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Ji, Zhengang ^a   Long, Hua ^a   Hu, Yunsheng ^a   Qiu, Xiuchun ^a   Chen, Xiang ^a   Li, Zhao ^a   Fan, Degang ^a   Ma, Baoan ^a   Fan, Qingyu ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; GLYCOPROTEIN P; HIF1A PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHORDOMA; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BIOSYNTHESIS; DRUG RESISTANCE; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; SACRUM; SPINAL CORD TUMOR; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CHORDOMA; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SACRUM; SPINAL NEOPLASMS;

EID: 78649803213     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-158     Document Type: Article

References (31)

1. Chordoma: the nonsarcoma primary bone tumor. R Chugh H Tawbi DR Lucas JS Biermann SM Schuetze LH Baker, Oncologist 2007 12 1344 1350 10.1634/ theoncologist.12-11-1344 18055855
2. Chordoma: natural history and treatment results in 33 cases. A Azzarelli V Quagliuolo S Cerasoli R Zucali P Bignami V Mazzaferro G Dossena L Gennari, J Surg Oncol 1988 37 185 191 10.1002/jso.2930370311 3352273
3. Chordoma: natural history and results in 28 patients treated at a single institution. D Baratti A Gronchi E Pennacchioli L Lozza M Colecchia M Fiore M Santinami, Ann Surg Oncol 2003 10 291 296 10.1245/ASO.2003.06.002 12679315 (Pubitemid 40486963)
4. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. C Cordon-Cardo JP O'brien D Casals L Rittman-Grauer JL Biedler MR Melamed JR Bertino, Proc Natl Acad Sci USA 1989 86 695 698 10.1073/pnas.86.2.695 2563168
5. Molecular responses to hypoxia in tumor cells. M Kunz SM Ibrahim, Mol Cancer 2003 2 23 10.1186/1476-4598-2-23 12740039
6. Hypoxia - a key regulatory factor in tumour growth. AL Harris, Nat Rev Cancer 2002 2 38 47 10.1038/nrc704 11902584
7. Hypoxia-inducible factor (HIF) in human tumorigenesis. NJ Mabjeesh S Amir, Histol Histopathol 2007 22 559 572 17330811
8. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. RL Jensen BT Ragel K Whang D Gillespie, J Neurooncol 2006 78 233 247 10.1007/s11060-005-9103-z 16612574
9. Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). DG Nagle YD Zhou, Curr Drug Targets 2006 7 355 369 10.2174/138945006776054979 16515532
10. Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1alpha-mediated tumor apoptotic switch. C Magnon P Opolon M Ricard E Connault P Ardouin A Galaup D Métivier JM Bidart S Germain M Perricaudet M Schlumberger, J Clin Inves 2007 117 1844 1855 10.1172/JCI30269 (Pubitemid 47036318)
11. Hypoxia and HIF-1alpha protect A549 cells from drug-induced apoptosis. SE Schnitzer T Schmid J Zhou B Brune, Cell Death Differ 2006 13 1611 1613 10.1038/sj.cdd.4401864 16456580
12. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. R Sullivan GC Paré LJ Frederiksen GL Semenza CH Graham, Mol Cancer Ther 2008 7 1961 1973 10.1158/1535-7163.MCT-08-0198 18645006
13. Establishment and characteristics of a human chordoma cell line. DZ Zhang BA Ma QY Fan H Chang YH Wen, Zhonghua Zhong Liu Za Zhi 2003 25 234 237 12839683
14. Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma. T Naka C Boltze A Samii M Samii C Herold H Ostertag Y Iwamoto Y Oda M Tsuneyoshi D Kuester A Roessner, Histopathology 2009 54 607 613 10.1111/j.1365-2559.2009.03278.x 19302530
15. Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells. Ding Zhenyu Yang Li Xie Xiaodong Xie Fangwei Pan Feng Li Jianjun He Jianming Liang Houjie, J Cancer Res Clin Oncol 2010 136 1697 1707 10.1007/s00432-010-0828-5 20217131
16. Hypoxia-inducible factor-1alpha is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal tumor. WT Chen CJ Huang MT Wu SF Yang YC Su CY Chai, Jpn J Clin Onco 2005 35 207 213 10.1093/jjco/hyi067 (Pubitemid 40796855)
17. Multidrug resistance proteins in renal cell carcinoma. I Hodorov S Rybrov P Solr J Vecanov J Mihalik P Bohus Y Mellov D Kluchov Folia Biol (Praha) 2008 54 187 192 19393132
18. Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. C Mignogna S Staibano V Altieri G De Rosa G Pannone A Santoro R Zamparese M D'Armiento R Rocchetti E Mezza M Nasti V Strazzullo V Montanaro M Mascolo P Bufo, BMC Cancer 2006 6 293 10.1186/1471-2407-6-293 17177989
19. Hypoxia inducible factor 1 alpha regulates matrigel-induced endovascular differentiation under normoxia in a human extravillous trophoblast cell line. K Fukushima M Murata M Hachisuga K Tsukimori H Seki S Takeda K Asanoma N Wake, Placenta 2008 29 324 331 10.1016/j.placenta.2008.01.006 18342368
20. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. H Enokida H Shiina M Igawa T Ogishima T Kawakami WW Bassett JW Anast LC Li S Urakami M Terashima M Verma M Kawahara M Nakagawa CJ Kane PR Carroll R Dahiya, Cancer Res 2004 64 5956 5962 10.1158/0008-5472.CAN-04-0081 15342374
21. Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy. N Larbcharoensub J Leopairat E Sirachainan L Narkwong T Bhongmakapat K Rasmeepaisarn T Janvilisri, Hum Pathol 2008 39 837 845 10.1016/j.humpath.2007.10.009 18400250
22. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. V Neaud S Faouzi J Guirouilh B Le Bail C Balabaud P Bioulac-Sage J Rosenbaum, Hepatology 1997 26 1458 1466 10.1002/hep.510260612 9397985
23. Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. GF Fleming PS Heimann JK Stephens MA Simon MK Ferguson RS Benjamin BL Samuels, Cancer 1993 72 714 718 10.1002/1097-0142(19930801)72:3<714::AID- CNCR2820720314 3.0.CO;2-1 8334623
24. A small prospective study of chordomas treated with radiotherapy and razoxane. W Rhomberg FK Böhler H Novak S Dertinger G Breitfellner, Strahlenther Onkol 2003 179 249 253 10.1007/s00066-003-1052-x 12707714
25. Oncogenic alteration of metabolism. CV Dang GL Semenza, Trends Biochem Sci 1999 24 68 72 10.1016/S0968-0004(98)01344-9 10098401
26. Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha. L Nardinocchi R Puca A Sacchi G Rechavi D Givol G D'Orazi, PLoS One 2009 4 6819 10.1371/journal.pone.0006819 19714248
27. c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1alpha dependent P-glycoprotein expression in hypoxia. KM Comerford EP Cummins CT Taylor, Cancer Res 2004 64 9057 9061 10.1158/0008-5472.CAN-04-1919 15604272
28. Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells. H Zhu XP Chen SF Luo J Guan WG Zhang BX Zhang, J Exp Clin Cancer Res 2005 24 565 574 16471319
29. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. X Song X Liu W Chi Y Liu L Wei X Wang J Yu, Cancer Chemother Pharmacol 2006 58 776 784 10.1007/s00280-006-0224-7 16532342
30. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. KM Comerford TJ Wallace J Karhausen NA Louis MC Montalto SP Colgan, Cancer Res 2002 62 3387 3394 12067980
31. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. JV Thottassery GP Zambetti K Arimori EG Schuetz JD Schuetz, Proc Natl Acad Sci USA 1997 94 11037 11042 10.1073/pnas.94.20.11037 9380755